Implementation of a mobile application in the Luxembourg Parkinson’s study for identification and validation of disease stage and variation
Objective: The project focuses on integrating a mobile application (mPower) into the Luxembourg Parkinson's cohort (HELP-PD) to monitor frequency and degree of variation in symptoms…Dopamine D3 receptor Ser9Gly variant is a risk factor for impulse control disorders in Parkinson’s disease
Objective: To test if the allelic variants of dopamine (DRD3), glutamate (GRIN2B) and serotonin (HTR2A) receptors are risk factors for ipulse control disorders (ICD) in…Protective effects of ATP13A2 in Parkinson’s disease models
Objective: Decipher the role of ATP13A2 in Parkinson's disease. Background: ATP13A2 is a lysosomal P-type ATPase with significant implications in Parkinson's disease (PD). Little is…Unconventional chaperone inhibits alpha-synuclein amyloid formation by promoting off-pathway aggregation
Objective: To find new potential druggable targets that prevent alpha-synuclein aggregation and toxicity in Parkinson's disease. Background: Alpha-synuclein (aS) is the primary protein deposited in…Physical training prevents depressive-like behavior and bdnf decrease in an animal model of Parkinson’s disease
Objective: The aim of this study was to investigate the effects of two types of physical training on depressive-like behavior and pro-BDNF, BDNF and its…Urate and homocysteine: Changes in motor and cognitive symptoms in newly diagnosed Parkinson’s disease
Objective: 1) To determine serum urate and homocysteine concentration at baseline, 18 and 36 months in control and PD participants. 2) To determine if urate…Effects of Arachidonyl-2′-chloroethylamide (ACEA), a selective CB1 receptor agonist, in MPTP mouse model of Parkinson’s disease
Objective: Cannabinoids have been demonstrated to be effective in preclinical studies involving oxidative stress, neuroinflammation, and motor complications associated with Parkinson's disease (PD).The CB1 cannabinoid…Treatment of OFF episodes in Parkinson’s disease: An evaluation of physician practices
Objective: Determine physician practices into the treatment of OFF episodes in patients with Parkinson's disease PD. Background: OFF episodes are fairly common in patients with…Molecular landscape of Parkinson’s disease reveals a key role for lipids and lipoproteins
Objective: Integrate available genetic and expression data to generate a molecular landscape of Parkinson's disease (PD) in order to identify key disease mechanisms that may…Prevalence of restless legs syndrome in an atypical Parkinson’s disease population
Objective: The aim of this study was to determine the prevalence of Restless Legs Syndrome (RLS) in patients with Multiple Systems Atrophy (MSA), Corticobasilar Degeneration…
- « Previous Page
- 1
- …
- 369
- 370
- 371
- 372
- 373
- …
- 388
- Next Page »